| Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents. | |
| | |
MedLine Citation:
|
PMID: 22248234 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Adolescent smoking remains a public health problem. Despite concerns regarding adolescent nicotine dependence, few well-designed smoking cessation studies have been conducted with teen smokers. This is particularly true regarding pharmacologic treatments for nicotine dependence. Currently, pharmacologic aids are not recommended for treating adolescent nicotine dependence, as efficacy has not been shown in this population. This review includes studies that have examined the efficacy of pharmacotherapy for smoking abstinence and/or reduction in cigarette consumption among adolescent smokers who want to quit smoking, laboratory-based adolescent studies that have examined the efficacy of these medications in reducing cravings and/or withdrawal symptoms, and/or studies that have assessed the tolerability of medications for smoking cessation in adolescent smokers. It provides information on the pharmacologic action of each medication, the efficacy of each medication for adolescent smoking cessation, the tolerability of each medication based on reported adverse events, and compliance with the medication protocols. Thirteen relevant articles were identified and included in the review. Nicotine patch (NP), nicotine gum, nicotine nasal spray, bupropion, and varenicline have been studied in adolescent smokers. The adverse events reported in the studies on pharmacology for adolescent smoking suggest that the side effect profiles for nicotine replacement therapy, bupropion, and varenicline are similar to those reported in adult studies. There is some evidence of efficacy of NP and bupropion at the end of treatment (efficacy of varenicline has not been assessed), but none of the medications included in this review were efficacious in promoting long-term smoking cessation among adolescent smokers. It is noted that many of the study protocols did not follow the recommended dose or length of pharmacotherapy for adults, rendering it difficult to determine the true efficacy of medication for adolescent smoking cessation. Future efficacy studies are warranted before recommending pharmacotherapy for adolescent smoking cessation. |
| | |
Authors:
|
Steffani R Bailey; Erin E Crew; Emily C Riske; Seth Ammerman; Thomas N Robinson; Joel D Killen |
Related Documents
:
|
8124174 - Drug and alcohol referrals: are elderly substance abuse diagnoses and referrals being m... 7382544 - Diagnosis of alcoholism with a self-administered alcoholism screening test: results wit... 2039024 - Medical problems of homeless and nonhomeless persons attending an inner-city clinic: a ... 17563214 - Family history and antisocial traits moderate naltrexone's effects on heavy drinking in... 9240574 - Nonobstetric conditions causing hypoxia during pregnancy: asthma and epilepsy. 16231724 - Serum gamma glutamyl transferase activity in horses with right or left dorsal displacem... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-16 |
Journal Detail:
|
Title: Paediatric drugs Volume: - ISSN: 1179-2019 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883685 Medline TA: Paediatr Drugs Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Oregon Health Science University, Department of Family Medicine, Portland, OR, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The antineurodegenerative agent clioquinol regulates the transcription factor FOXO1a.
Next Document: Clinical and radiological differences in posterior reversible encephalopathy syndrome between patien...